CBT Market Analysis and Reports | Canada Conference Series

Market Analysis - CBT 2017

Importance and Scope:

National Survey on Drug Use and Health (NSDUH) also found in 2008 that just over half (58.7 percent) of adults in the United States with a serious mental illness (SMI) received treatment for a mental health problem. Treatment rates for SMI differed across age groups, and the most common types of treatment were outpatient services and prescription medication. About 71 percent of adults who had major depression used mental health services and treatment to help with their disorder

Conferences, National symposiums and Workshops provide a dedicated forum for the advancement, execution and exchange of information about brain disorders and its allied areas.

There are a number of treatments available which can be used to help those suffering from a mental health concern. Antidepressants are a common form of treatment for neurotic and psychotic disorders, but talking therapies are becoming an increasingly popular method of treatment, either when used on their own or when used in conjunction with prescribed medication.

The unexamined life may not be worth living, but the over examined life can be difficult, too. Many people are turning to a relatively young branch of “talking therapy”, called Cognitive Behavioural Therapy (CBT) to get them through the (day and) night. CBT, which teaches people to bypass unhelpful thoughts, has been elbowing aside the talk-about-your-childhood psychoanalysis favoured by believers in Freud and Jung. Up to 43% of all therapy courses in Britain are now CBT, and the practice is increasing: around 6,000 new therapists have been trained since 2007 and CBT absorbs much public funding. In 2012, £213m went on a National Health Service programme delivering CBT, while £172m was spent on all other forms of psychoanalysis and psychotherapy. The growing popularity of CBT was consolidated in 2007, when the government adopted the treatment as standard. Three things had swayed it. The new practice had accumulated a body of evidence proving it worked (students of Freud and Jung have been slower to move from couch to lab). It was very good at getting patients back to the office: a 1997 study found people with psychological problems had significantly higher employment rates after CBT than after traditional psychoanalysis. It was also speedy, getting results after just ten one-hour sessions (psychoanalysis can, expensively, take a lifetime). So CBT therapists were trained up and given all the plum NHS jobs, consigning other therapies largely to private practice.

Why to attend???

CBT-2017 will provide an opportunity for all stakeholders working on mental health issues to talk about their work.  CBT -2017 will congregate renowned speakers, principal investigators, experts, psychiatrist and researchers from both academia and health care industry will join together to discuss their views and research. The conference will be comprised of sessions by world class experts in the field of psychotherapy. In CBT -2017, international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Psychiatry and cognitive therapy.

A Unique Opportunity for Advertisers and Sponsors at this International event:


Major Psychological & Mental health Associations and Societies in Canada:

Canadian Positive Psychology Association

Canadian Psychological Association

Psychologists' Association of Alberta

British Columbia Psychological Association

Manitoba Psychological Society

Association of Psychologists of Nova Scotia

Psychology Societies and Associations around the Globe

There are approximately 200 Psychological & Psychiatric association’s globally which deals with various Psychological & Psychiatric disorders. Few of them are:

American Psychological Association

Canadian Psychological Association

International Positive Psychology Association

New Zealand Association of Positive Psychology

Indian Association of Positive Psychology

National Positive Psychology Association

Western Positive Psychology Association

American Academy of Child and Adolescent Psychiatry

American Psychiatric Association


Target Audience:

Industry       10%

Academia    50%

Clinicians     20%

Others          10%

University    10%


Universities in Toronto, Ontario related to Psychology are:

  • Ryerson University
  • University of Toronto
  • Yorkville University
  • University of Toronto – Scarborough
  • University of Windsor
  • University of Guelph
  • Wilfrid Laurier University
  • Trent University
  • McMaster University
  • University of Western Ontario
  • Royal Military College of Canada
  • University of Waterloo
  • University of Ottawa
  • Redeemer University College
  • Queen's University
  • Lakehead University
  • York University – Glendon
  • Carleton University
  • St. Jerome's University

List of Hospitals associated with Psychology, Psychiatry & Mental Health in Toronto, Ontorio are:

  • Centre for Addiction and Mental Health
  • Lakeshore Psychiatric Hospital
  • Ontario Shores Centre for Mental Health Sciences
  • Whitby Psychiatric Hospital
  • Waypoint Centre for Mental Health Care
  • Royal Ottawa Mental Health Centre
  • Huronia Regional Centre
  • St Joseph's Health Centre
  • St. Michael's Hospital
  • Homewood Health Centre
  • Applied Psychology Centre
  • Toronto General Hospital (TGH)


In the OECD, around two-thirds of research and development in scientific and technical fields is carried out by industry, and 20% and 10% respectively by universities and government, although in poorer countries. Often research funding is applied for by scientists and approved by a granting agency to financially support research. These grants require a lengthy process as the granting agency can inquire about the researcher(s)'s background, the facilities used, the equipment needed, the time involved, and the overall potential of the scientific outcome. The process of grant writing and grant proposing is a somewhat delicate process for both the granter and the grantee: the granter wants to choose the research that best fits their scientific principles, and the grantee wants to apply for research in which she has the best chances but also in which she can build a body of work towards future scientific endeavours. This interplay can be a frustrating and lengthy process.

Market Value on Psychological & Mental health Research Globally:

The global market for Psychiatric & mental health drugs was worth $80.5 billion in 2010 and that value is worth to be $88.3 billion in 2015. The global Behavioral health software market in 2014 is $0.75 billion and is expected to reach $1.5 billion by 2019.

Market Growth of Psychology Research in the last and upcoming ten years

North America has the biggest market for mental health software, preceded by Europe. According to BBC research the global market for drugs treating mental disorders was valued as $70.1 billion in 2012 and is estimated to have declined slightly too nearly $69 billion in 2013 and by 2018 it aims the market growth approximately to $77.1 billion.

Projection: Growth by next 5-10 years

AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Johnson & Johnson, and GlaxoSmithKline. Eli Lilly: Zyprexa drug has the largest market share of the market, at 26% ($4.70 billion). AstraZeneca: Seroquel, at 2nd place ($4.45 billion) remains the most widely prescribed antipsychotic. Bristol-Myers Squibb: Abilify, saw a 30% growth in sales from 2007 to 2008 to $2.15 billion. Zyprexa earned revenues of $4.70 billion in 2008, representing 23% of Eli Lilly's total earnings in that year. Total sales for Zyprexa decreased 1% from 2007 to 2008, due to decreased demand from increased generic competition. Zyprexa was approved in 2000 to treat schizophrenia. Eli Lilly's patent for Zyprexa expires on April 23, 2011. Abilify earned revenues of $2.15 billion in 2008 for a growth of 30% from 2007 to 2008. Abilify was approved in 2007 as an adjunctive treatment for major depressive disorder as well as a therapeutic for schizophrenia and bipolar disorder in adolescents. J&J's antipsychotics franchise, including the Risperdal formulations and Invega, earned revenues of $3.8 billion in 2008; a decrease of 24% from 2007 to 2008. Invega was approved in 2007 by the FDA to treat schizophrenia.

Products manufactured by the industry related to Psychiatric & Psychological Mental Disorders are;

  • Zyprexa
  • Zyprexa Relprevv
  • Zyprexa Zydis